Paul-Peter Tak

Paul-Peter Tak is Board Director of Levicept. He has served as President and Chief Executive Officer and as a member of the board of directors of Candel Therapeutics since September 2020; he oversaw the IPO process on the Nasdaq in 2021.

He received his medical degree cum laude from the Amsterdam University Medical Center and was trained as an internist, rheumatologist, and immunologist at Leiden University Medical Center, where he also received his Ph.D. Dr. Tak has been Clinical Associate Professor of Medicine at the University of California San Diego. Next, he served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Amsterdam University Medical Center. Dr. Tak has pioneered preclinical and clinical research on the role of the vagus nerve in chronic inflammation. This work provided a platform from which to explore bioelectronics as a therapeutic approach in autoimmune disease.

He has published ~600 papers in peer-reviewed journals (H-index 144) and received numerous awards. He has been elected Fellow of the Academy of Medical Sciences (U.K.). At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. In his role as Global Head of a cluster of Therapy Area Units at GSK he oversaw the creation of a portfolio of new medicines for immune-mediated inflammatory diseases, cancer, and infectious diseases. He was also the Chair of the Scientific Review Board. Dr Tak was also the President and CEO of Tempero Pharmaceuticals (acquired by GSK), and served as venture partner at Flagship Pioneering and also as President and CEO of Kintai Therapeutics (merged with Senda Biosciences). In addition, he has served as board director of Galvani Bioelectronics ViiV Healthcare, and Omega Therapeutics. Currently, he is on the Board of Sitryx Therapeutics (co-founder), Levicept, and he is the Chair of the Board of Citryll.